Introduction: Hypertriglyceridemia is a frequent dyslipidemia in type 2 diabetes. We aimed to determine its prevalence, its typology, and its associated factors in newly type 2 diabetes patients in Ouagadougou. Material and Method: This cross-sectional, descriptive and analytic study has been performed from May 2015 to June 2016 in the Internal medicine department in Yalgado Ouédraogo teaching hospital, Ouagadougou. An accidental sample of newly type 2 diabetes outpatients, na?ve of antidiabetics therapy was studied. A 12-hour fasting triglyceridemia was performed; hypertriglyceridemia was defined for triglyceridemia > 1.5 g/L (1.7 mmol/L). Data were analyzed with Epi info 7.1.5.0. Proportions and means were compared respectively with Khi2 or Fisher’s test and Student’s test with a significance of p < 5%. Results: One hundred and three patients, i.e. 35 (34%) men and 68 (66%) women were included. The sex ratio was 0.51 and the mean age 49.3 ± 10.1 years [limits: 24 and 70]. The mean value of triglyceridemia was 1.8 ± 1.7 mmol/L [limits: 0.5 and 14.9]. Hypertriglyceridemia was reported in 32 patients (31.1%): minor (<4.52 mmol/L) in 26 (81.3%), moderate (between 4.52 and 11.30 mmol/L) in five (15.6%) and severe (>11.30 mmol/L) in one (3.1%) patients. Hypertriglyceridemia’s phenotype was commonly integrated into a mixed dyslipidemia; it was often combined with a total cholesterolemia increase and a HDL cholesterolemia decrease. In bivariate analysis, hyperglycemia was associated with severe hyperglycemia (p = 0.006) and renal failure (p = 0.03). Conclusion: Hypertriglyceridemia in type 2 diabetes is frequent and often combined with other lipids disorders. It may need an optimal care.
References
[1]
Tanguy, B. and Aboyans, V. (2014) Dyslipidémie et diabète. Réalités Cardiologiques, 303, 37-41. http://www.realites-cardiologiques.com/
[2]
Nordestgaard, B.G. (2016) Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights from Epidemiology, Genetics, and Biology. Circulation Research, 118, 547-563. https://doi.org/10.1161/CIRCRESAHA.115.306249
[3]
Ziegler, O. Hypertriglycéridémies et risque vasculaire. Hypertriglycéridémies et risque vasculaire. http://Institutdanone.org
[4]
Ferrari, R., Aguiar, C., Alegria, E., et al. (2016) Current Practice in Identifying and Treating Cardiovascular Risk, with a Focus on Residual Risk Associated with Atherogenic Dyslipidaemia. European Heart Journal Supplements, 18, C2-C12. https://doi.org/10.1093/eurheartj/suw009
[5]
Cugnet-Anceau, C., Moret, M. and Moulin, P. (2011) Existeil un risque de pancréatite aiguë? Conduite à tenir devant une hypertriglycéridémie. Revue du Praticien, 1110-1116.
[6]
Daniel, M., Paquet, C., Kelly, S.J., Zang, G., Rowley, K.G., McDermott, R., et al. (2013) Hypertriglyceridemic Waist and Newly-Diagnosed Diabetes among Remote-Dwelling Indigenous Australians. Annals of Human Biology, 40, 496-504. https://doi.org/10.3109/03014460.2013.806588
[7]
Tian, J., Chen, H., Jia, F., Yang, G., Li, S., Li, K., et al. (2015) Trends in the Levels of Serum Lipids and Lipoproteins and the Prevalence of Dyslipidemia in Adults with Newly Diagnosed Type 2 Diabetes in the Southwest Chinese Han Population during 2003-2012. International Journal of Endocrinology, 2015, 1-7. https://doi.org/10.1155/2015/818075
[8]
Després, J.P., Couillard, C., Gagnon, J., Bergeron, J., Arthur, S. and James, S. (2000) Race, Visceral Adipose Tissue, Plasma Lipids, and Lipoprotein Lipase Activity in Men and Women. The Health, Risk Factors, Exercise Training, and Genetics (HERITAGE) Family Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 20, 1932-1938. https://doi.org/10.1161/01.ATV.20.8.1932
[9]
Morrison, J.A., Barton, B.A., Biro, F.M. and Sprecher, D. (1998) The Conjoint Trait of Low High-Density Lipoprotein Cholesterol and High Triglycerides in Adolescent Black and White Males. Metabolism, 47, 514-521. https://doi.org/10.1016/S0026-0495(98)90233-5
[10]
Valdigue, P. (2000) Biochimie clinique. 2nd Edition, Toulouse. Edition médicales internationals, 332 p.
[11]
Boland, B., Chenu, P. and Descamps, O. (2001) Les dyslipidémies en médecine générale: détection, attitude et traitement. Louvain Médical, 119, 79-90.
[12]
Qie, L.Y., Sun, J.P., Ning, F., Pang, Z.C., Gao, W.G., Ren, J., et al. (2014) Cardiovascular Risk Profiles in Relation to Newly Diagnosed Type 2 Diabetes Diagnosed by Either Glucose or HbA1c Criteria in Chinese Adults in Qingdao, China. Diabetic Medicine, 31, 920-926. https://doi.org/10.1111/dme.12498
[13]
Vergès, B. (2007) Physiopathologie de la dyslipidémie du syndrome métabolique et du diabète de type 2. Nutrition Clinique et Métabolisme, 21, 9 16. https://doi.org/10.1016/j.nupar.2007.01.011
[14]
Radermecker, R., Philips, J.-C., Jandrain, B., Paquot, N. and Scheen, A. (2008) L’étude clinique du mois. Contrôle glycémique et morbimortalité cardiovasculaire chez le patient diabétique de type 2. Résultats des études ACCORD, ADVANCE et VA-Diabetes. Revue médicale de Liège, 63, 511-518.
[15]
Beressi, J.-P. Choix d’un antihypertenseur dans l’HTA associée à une dyslipidémie. http://www.edimark.fr/Front/frontpost/getfiles/88.pdf